Madrigal Pharmaceuticals (MDGL) Competitors $300.15 -0.01 (0.00%) Closing price 04:00 PM EasternExtended Trading$299.52 -0.63 (-0.21%) As of 05:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock MDGL vs. BIIB, INCY, UTHR, NBIX, EXEL, BMRN, EXAS, RGEN, HALO, and IONSShould you be buying Madrigal Pharmaceuticals stock or one of its competitors? The main competitors of Madrigal Pharmaceuticals include Biogen (BIIB), Incyte (INCY), United Therapeutics (UTHR), Neurocrine Biosciences (NBIX), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Ionis Pharmaceuticals (IONS). These companies are all part of the "biotechnology" industry. Madrigal Pharmaceuticals vs. Its Competitors Biogen Incyte United Therapeutics Neurocrine Biosciences Exelixis BioMarin Pharmaceutical Exact Sciences Repligen Halozyme Therapeutics Ionis Pharmaceuticals Biogen (NASDAQ:BIIB) and Madrigal Pharmaceuticals (NASDAQ:MDGL) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, profitability, valuation, dividends, institutional ownership and earnings. Do insiders & institutionals hold more shares of BIIB or MDGL? 87.9% of Biogen shares are owned by institutional investors. Comparatively, 98.5% of Madrigal Pharmaceuticals shares are owned by institutional investors. 0.2% of Biogen shares are owned by company insiders. Comparatively, 21.5% of Madrigal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Do analysts rate BIIB or MDGL? Biogen presently has a consensus target price of $188.48, indicating a potential upside of 41.51%. Madrigal Pharmaceuticals has a consensus target price of $420.63, indicating a potential upside of 40.14%. Given Biogen's higher possible upside, analysts clearly believe Biogen is more favorable than Madrigal Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biogen 0 Sell rating(s) 20 Hold rating(s) 12 Buy rating(s) 0 Strong Buy rating(s) 2.38Madrigal Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89 Which has higher valuation and earnings, BIIB or MDGL? Biogen has higher revenue and earnings than Madrigal Pharmaceuticals. Madrigal Pharmaceuticals is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiogen$9.68B2.02$1.63B$10.1313.15Madrigal Pharmaceuticals$180.13M36.99-$465.89M-$18.05-16.63 Is BIIB or MDGL more profitable? Biogen has a net margin of 15.07% compared to Madrigal Pharmaceuticals' net margin of -123.38%. Biogen's return on equity of 14.03% beat Madrigal Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Biogen15.07% 14.03% 8.32% Madrigal Pharmaceuticals -123.38%-50.54%-37.19% Which has more risk and volatility, BIIB or MDGL? Biogen has a beta of 0.14, meaning that its stock price is 86% less volatile than the S&P 500. Comparatively, Madrigal Pharmaceuticals has a beta of -1.05, meaning that its stock price is 205% less volatile than the S&P 500. Does the media prefer BIIB or MDGL? In the previous week, Biogen had 25 more articles in the media than Madrigal Pharmaceuticals. MarketBeat recorded 29 mentions for Biogen and 4 mentions for Madrigal Pharmaceuticals. Madrigal Pharmaceuticals' average media sentiment score of 0.97 beat Biogen's score of 0.91 indicating that Madrigal Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biogen 17 Very Positive mention(s) 1 Positive mention(s) 10 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Madrigal Pharmaceuticals 1 Very Positive mention(s) 2 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryBiogen beats Madrigal Pharmaceuticals on 11 of the 16 factors compared between the two stocks. Get Madrigal Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for MDGL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MDGL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MDGL vs. The Competition Export to ExcelMetricMadrigal PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$6.66B$2.42B$5.49B$8.94BDividend YieldN/A1.79%5.38%4.13%P/E Ratio-16.638.9526.2119.90Price / Sales36.99663.84415.20165.00Price / CashN/A154.3736.4957.06Price / Book8.684.548.055.38Net Income-$465.89M$31.16M$3.15B$248.50M7 Day Performance8.11%0.16%1.93%2.99%1 Month Performance10.08%8.82%4.91%6.03%1 Year Performance10.48%2.56%35.87%20.40% Madrigal Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MDGLMadrigal Pharmaceuticals3.9798 of 5 stars$300.150.0%$420.63+40.1%+7.5%$6.66B$180.13M-16.6390BIIBBiogen4.9602 of 5 stars$124.76-1.8%$188.19+50.8%-43.9%$18.61B$9.68B12.327,605INCYIncyte4.368 of 5 stars$67.26-1.8%$74.53+10.8%+12.9%$13.25B$4.24B210.192,617UTHRUnited Therapeutics4.9948 of 5 stars$286.39-1.5%$393.08+37.3%-8.8%$13.11B$2.88B11.431,305Positive NewsAnalyst ForecastNBIXNeurocrine Biosciences4.9381 of 5 stars$125.80-0.6%$162.00+28.8%-8.6%$12.52B$2.36B42.641,800Positive NewsEXELExelixis4.743 of 5 stars$43.37+7.4%$41.00-5.5%+96.0%$11.01B$2.17B19.711,147Positive NewsAnalyst ForecastGap UpHigh Trading VolumeBMRNBioMarin Pharmaceutical4.9595 of 5 stars$54.08-1.7%$93.45+72.8%-31.6%$10.55B$2.85B20.103,040Positive NewsEXASExact Sciences4.9182 of 5 stars$52.54-0.9%$70.90+34.9%+28.7%$10.00B$2.76B-9.547,000Positive NewsAnalyst RevisionRGENRepligen4.8041 of 5 stars$120.11+1.1%$173.25+44.2%+2.5%$6.68B$634.44M-266.911,778Positive NewsAnalyst DowngradeHALOHalozyme Therapeutics4.8115 of 5 stars$52.800.0%$61.90+17.2%+1.7%$6.51B$1.02B14.04390Analyst RevisionIONSIonis Pharmaceuticals4.5989 of 5 stars$37.67+0.7%$57.59+52.9%-15.2%$5.95B$705M-12.601,069News CoverageAnalyst Upgrade Related Companies and Tools Related Companies Biogen Competitors Incyte Competitors United Therapeutics Competitors Neurocrine Biosciences Competitors Exelixis Competitors BioMarin Pharmaceutical Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Ionis Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MDGL) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersGet Your Bank Account “Fed Invasion” Ready with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredTrump’s Exec Order #14154 could be a “Millionaire-Maker”Former Presidential Advisor, Jim Rickards, says Trump could “rewire our economy and hand millions of Americans...Paradigm Press | SponsoredThe $100 Trillion AI Story No One Is Telling YouJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredSomething very strange is happening...What a "Mar-a-Lago Accord" could mean for the U.S. dollar While protests dominate the news... hardly anyone...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Madrigal Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Madrigal Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MDGL Stock Alerts